Evidence map›Paper›PMID 25002260›Full record

ArticleBiomaterials2014

Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices.

Matthew Joseph, Manjusri Das, Suman Kanji, Jingwei Lu, Reeva Aggarwal, Debanjan Chakroborty, Chandrani Sarkar, Hongmei Yu, Hai-Quan Mao, Sujit Basu and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Current advances in ischemic stroke research and therapies.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  3. Nanofiber-expanded human CD34Scientific reports · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Matthew JosephStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Manjusri DasStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Suman KanjiStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Jingwei LuStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Reeva AggarwalStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Debanjan ChakrobortyDepartment of Pathology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Chandrani SarkarDepartment of Pathology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Hongmei YuDepartment of Pathology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Hai-Quan MaoDepartment of Materials Science and Engineering & Whitaker Biomedical Engineering Institute, Johns Hopkins University, Baltimore, MD, USA.
Sujit BasuDepartment of Pathology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Vincent J PompiliStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
Hiranmoy DasStem Cell Research Laboratory, Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Columbus, OH, USA. Electronic address: hiranmoy.das@osumc.edu.

Funding

Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells iR44HL092706 · NHLBI · ARTERIOCYTE, INC. · PI COOPER, CHRISTOPHER J, POMPILI, VINCENT J · 2008 to 2011
$2.5M
KLF2 as a novel regular for monocyte activation and functionK01AR054114 · NIAMS · OHIO STATE UNIVERSITY · PI DAS, HIRANMOY · 2008 to 2012
$670k
Novel Markers of Anthracycline-induced Myocardial DamageR21CA143787 · NCI · OHIO STATE UNIVERSITY · PI SHAPIRO, CHARLES L. · 2010 to 2011
$632k
NCI NIH HHS R21 CA143787NHLBI NIH HHS R44 HL092706NHLBI NIH HHS R44 HL092706-01NIAMS NIH HHS K01 AR054114
6 · The paper itself

Abstract

Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133(+)/CD34(+) progenitor cells ∼225 fold. Herein, we show that using similar technology and subsequent re-expansion methods, we can achieve ∼5 million-fold yields within 24 days of the initial seeding. Interestingly, stem cell phenotype was preserved during the course of the multiple expansions. The high level of the stem cell homing receptor, CXCR4 was expressed in the primary expansion cells, and was maintained throughout the course of re-expansions. In addition, re-expanded cells preserved their multi-potential differential capabilities in vitro, such as, endothelial and smooth muscle lineages. Moreover, biological functionality of the re-expanded cells was preserved and was confirmed by a murine hind limb ischemia model for revascularization. These cells could also be genetically modified for enhanced vasculogenesis. Immunohistochemical evidences support enhanced expression of angiogenic factors responsible for this enhanced neovascularization. These data further confirms that nanofiber-based ex-vivo expansion technology can generate sufficient numbers of biologically functional stem cells for potential clinical applications.

Indexed as

AnimalsCell DifferentiationCell ProliferationCell ShapeHumansHuman Umbilical Vein Endothelial CellsImmunohistochemistryIschemiaMice, SCIDMultipotent Stem CellsNanofibersNeovascularization, PhysiologicPhenotypePolymersStem CellsSulfonespolyether sulfonePolymersSulfonesCD34(+) stem cellsLimb ischemiaNOD/SCID micePES-nanofiberProangiogenic growth factorsRe-expansion

Identifiers

PMID25002260
PMCPMC4131920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.